Treatment of Steroid Refractory Gastro-intestinal Acute Graft-versus-Host disEase afteR AllogeneiC Hematopoietic Stem celL Transplantation With fEcal Microbiota tranSfer
Phase of Trial: Phase II
Latest Information Update: 06 Nov 2019
Price : $35 *
At a glance
- Drugs Maa-T-013 (Primary)
- Indications Graft-versus-host disease
- Focus Proof of concept; Therapeutic Use
- Acronyms HERACLES
- Sponsors MaaT Pharma
- 06 Nov 2019 According to an MaaT Pharma media release, initial data from this study was published online in the November supplemental issue of the journal Blood.
- 06 Nov 2019 According to an MaaT Pharma media release, initial data from this study will be presented at the 61st American Society of Hematology (ASH) Annual Meeting.
- 24 Jun 2019 According to a MaaT Pharma media release, the company has announced the third positive assessment of this study by an independent Data and Safety Monitoring Board (DSMB). Following the second review in April with 10 patients, this review confirms the absence of safety issues during the trial after 15 patients treated.